ZOLADEX(GOSERELIN) LA DEPOT 10.8MG INJECTION

Therapeutic indications (i) Treatment of prostate cancer in the following settings (see also section 5.1): In the treatment of metastatic prostate cancer where Zoladex has demonstrated comparable survival benefits to surgical castrations. In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Zoladex has demonstrated comparable survival benefits to an anti-androgen. As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival and overall survival. As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival. As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where Zoladex has demonstrated improved disease-free survival. (ii) ZOLADEX LA 10.8 mg is indicated in the management of oestrogen-receptor (ER) positive early and advanced breast cancer in pre and peri menopausal women.  

KES 39,383.00

(Inclusive of all taxes)